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Abstract: Urolithin A (UroA) is a gut metabolite produced from ellagic acid-containing foods such 
as pomegranates, berries, and walnuts. UroA is of growing interest due to its therapeutic potential 
for various metabolic diseases based on immunomodulatory properties. Recent advances in UroA 
research suggest that UroA administration attenuates inflammation in various tissues, including the 
brain, adipose, heart, and liver tissues, leading to the potential delay or prevention of the onset of 
Alzheimer’s disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. In this review, 
we focus on recent updates of the anti-inflammatory function of UroA and summarize the potential 
mechanisms by which UroA may help attenuate the onset of diseases in a tissue-specific manner. 
Therefore, this review aims to shed new insights into UroA as a potent anti-inflammatory molecule 
to prevent immunometabolic diseases, either by dietary intervention with ellagic acid-rich food or 
by UroA administration as a new pharmaceutical drug. 
Keywords: urolithin A; insulin resistance; mitochondria; inflammation; lipid metabolism; nutri-
tional sciences; obesity; metabolic syndrome 
 
1. Introduction 
Urolithin (Uro) production results from the bioconversion of ellagic acid through gut 
microbes. Ellagic acid (EA) is a polyphenol found in foods such as berries, pomegranates, 
and walnuts, and consumption of ellagic acid (EA)-rich foods yields ellagitannins (ETs), 
which hydrolyze in the stomach [1–3]. EA freely circulates in the stomach, and a propor-
tion of EA reaches the small intestine and undergoes gut microbial conversion [4]. Due to 
low bioavailability of dietary polyphenols, the health benefits from pomegranate con-
sumption are attributed to the released gut metabolites rather than the polyphenols per 
se [5]. 
The Uro family includes UroM-5, UroD, UroM-6, UroE, UroC, UroM-7, Iso-UroA, 
UroB, and UroA [6,7]. Recently, new “R” urolithins were discovered and classified as uro-
lithin M7R, urolithin CR, and urolithin AR, thereby advancing knowledge regarding the 
various “metabotypes” which consist of producers collectively (UM-B) followed by non-
producers labeled as metabotype 0 (UM-0) [6,8]. Uros possess a common 6H-dibenzo 
[b,d]-pyran-6-one nucleus and differ by hydroxyl groups [9]. Once absorbed, urolithins 
reach the liver and undergo phase 2 biotransformation, to yield various conjugated forms. 
For UroA, conjugated forms include UroA-glucuronide and UroA-aglycones [5]. Our re-
view focuses on UroA because its conjugates are found at the highest concentrations in 
human plasma ranging from 0.024 to 35 μM [9]. This review aims to compile UroA’s anti-
inflammatory role based on recent in vitro and in vivo studies. We specifically discuss 
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UroA’s ability to combat inflammation within immune function, neurological disease, 
obesity, obesity-related metabolic syndrome, and cardiovascular disease.  
2. Current Status of Knowledge 
2.1. Pharmacokinetics of UroA 
Urolithins are produced from ellagic-acid containing foods undergoing gut microbial 
conversion and vary in concentrations among individuals [10]. Once EA-containing foods 
reach the colon, the gut-derived metabolite UroA and its conjugates exert anti-inflamma-
tory and anti-angiogenic activities, unlike UroA’s parental compound EA [11,12] (Figure 
1). Moreover, methylated UroA inhibits miR-21 expression and its downstream targets to 
suppress prostate cancer progression [13]. In recent years, studies reported specific gut 
bacteria result in the production of UroA. As the story of UroA unfolds, researchers found 
specific gut metabotypes are associated with the release of specific urolithins, including 
UroA, iso-UroA, and UroB [14]. Individuals classified as metabolically healthy (i.e., with-
out metabolic syndrome conditions) release higher concentrations of active UroA, there-
fore belonging to metabotype A [8,15]. Interestingly, those classified as metabolically un-
healthy produce minimal urolithin A and release the less active forms of urolithin includ-
ing iso-UroA and UroB, thus belonging to metabotype 0 and metabotype B, respectively 
[8,15]. Based on the correlations between metabotypes and metabolites, it suggests the gut 
microbial community may play a greater role in determining the production of active 
UroA. Of these microbes, Gordonibacter urolithinfaciens and Gordonibacter pamelaeae are in-
volved in converting ellagic acid to UroA [16,17]. Akkermansia muciniphila levels are re-
ported to be associated with UroA levels but can vary in UroA activity depending on in-
ter-individual differences [18,19]. Based on this evidence, UroA production and activity 
may be associated with the gut microbial community and metabotype classification; how-
ever, more research is needed to provide stronger associations. 
UroA possesses the ability to provide various health benefits to the host due to its 
specific chemical structure including acting as an estrogenic agonist identified through 
ligand docking, suggesting UroA’s potential ability to modulate endocrine activity [20]. 
Additionally, UroA is a natural microbiota-derived human-selective aryl hydrocarbon re-
ceptor ligand and aryl hydrocarbon receptors are expressed by numerous cells, including 
immune cells [21]. In connection with aryl hydrocarbon receptors, UroA induces the ex-
pression of various genes associated with phase 1 and phase 2 metabolism, also known as 
xenobiotic metabolism [22]. Through its ability to induce xenobiotic metabolism, UroA 
could potentially be a useful metabolite in attenuating disease through therapeutics. 
As UroA research advances, the use of UroA therapeutics arises and highlights the 
importance of bioavailability and effectiveness of this metabolite. UroA has been demon-
strated to reach peripheral tissues both through oral administration and injections; how-
ever, several studies classify UroA’s actions as dependent on its conjugation with glucu-
ronide, aglycone, or sulfation [9,23]. This notion was recently challenged, as researchers 
have demonstrated that free UroA reaches peripheral tissues, thereby suggesting decon-
jugation from UroA glucuronide [23]. Specifically, in inflammatory conditions, conju-
gated UroA converts into free UroA to exert its health benefits in tissues other than the 
intestine [23] (Figure 1). Therefore, we focus on UroA’s ability to modulate inflammation 
in various cell types and tissues, including studies reporting both free UroA and its con-
jugated forms since more research regarding UroA’s pharmacokinetics and attenuation of 
disease is warranted. 
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Figure 1. Ellagic-acid containing foods undergo gut microbial conversion to yield various forms of urolithins (Uro). Uro-
lithin A (UroA) enters circulation and reaches the liver, to undergo phase II metabolism, to yield conjugated forms of 
UroA (such as methylation, glucuronidation, and sulfation). Conjugated UroA is able to reach peripheral tissues, including 
the adipose, brain, and muscle tissue, to prevent inflammation and increase mitochondrial function. Created with BioRen-
der.com. UroA, urolithin A; UroB, urolithin B; UroD, urolithin D. 
2.2. Immunomodulatory Function of UroA 
Innate immune system activation is crucial for acute danger signals in response to 
injury or trauma; however, under chronic activation, this can lead to cell cytotoxicity. One 
mechanism of the innate immune system utilizes myeloperoxidase (MPO) which is ex-
pressed in neutrophils [24]. Upon respiratory burst of neutrophils, MPO mediates the gen-
eration of H2O2 to kill bacteria; however, under circumstances of chronic activation, in-
flammation and tissue damage ensue [24,25]. Saha et al. investigated whether UroA in-
hibits the generation of toxic H2O2 and inflammation. Using a phorbol myristate acetate 
(PMA)-induced ear edema model in mice, researchers observed that 40 mg/kg of UroA 
before the onset of edema was enough to inhibit heme peroxidases by inactivating the 
peroxidase-catalyzed reaction and subsequent unnecessary generation of reactive oxygen 
species (ROS) in neutrophils [26]. Furthermore, in human neutrophils, UroA decreased 
ROS production in response to lipopolysaccharide (LPS) stimulation, suggesting anti-ox-
idative properties and potential in modulating neutrophil function [27]. In all, UroA exerts 
protection against oxidative stress and pro-inflammatory stimuli. 
Similar to the actions in neutrophils, UroA inhibited the generation of LPS-induced 
ROS in murine macrophages and peritoneal macrophages [28]. UroA suppressed pro-in-
flammatory cytokines, including tumor necrosis factor alpha (TNFα) and interleukin 6 
(IL6), decreased nitrite and inducible nitric oxide synthase (iNOS) production, by inhibit-
ing the activation of NFκB signaling pathways [28]. Consistently, studies reported UroA’s 
ability to suppress the protein kinase B (Akt)/mitogen-activated protein kinase (MAPK) 
signaling pathways by either modulating the nuclear translocation of NFκB, inhibiting 
pro-inflammatory cytokine production, or reducing oxidative stress in various immune 
cells [28–33]. In supporting this notion, multiple research studies confirm UroA as a potent 
mediator to reduce inflammation associated with innate immunity and ROS production, 
as found in Table 1. 
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Table 1. Immunomodulatory function of UroA. 









40 mg/kg/BW orally 
10 μM (BMDM) 
↓ MPO activity and LPO activity with iron chelation 
[26] 
↓ ear edema weight (mg) 
Immune 





↓ IL-18 production (%), MMP-9 production (%), MPO release (%) 
↓ ROS release (%) 
↓ Superoxide anion production activity (%) and  










↓ TNFα, IL-6, nitrite, iNOS  
↓ DNA binding response to LPS, LPS induced translocation of p65 
↑ IkBα  
↓AP-1 DNA binding activity, c-JUN and p-c-JUN  
↓ p-Akt, p-JNK, p-p38  













20 mg/kg/day intragastric 
administration 
 
↓ Il-1β, iNOS, Cox-2, NO generation, PG32 
↓ IkBα degradation and translocation of P65 to nucleus 
↓ PI3K/Akt signaling pathway 
↓ p-PI3K and p-AKT-positive chondrocytes in mouse 
↓ p65-positive nuclei in UA mouse chondrocytes; milder narrowing 
of joint space compared to OA group 
[29] 
Immune Rat chondrocytes Osteoarthritis 1–15 μM 
↓ MMP13, MMP3, iNOS, Cox2, ADAMST4, MMP9  
↑ Col2a1  
↑ Collagen II, Aggrecan, Sox9  







1.5, 30 μM 
↓ Tnfα 
↓ NFκB signaling, p50 and p60 subunits 
[31] 
Immune 
RAW 264.7 murine 
macrophages 
LPS inflam-
mation 2–40 μM 
↓ NO production, nitrite, iNOS  
↓ NF-κB p65 nuclear translocation  
↓ binding to NFκB p50 binding  
↓ IL-1β, TNFα, IL-6 
[32] 
Immune 

















↓ NO release, ROS, pro-IL-1β 
↑ LC3 II activation 
↓ p-AKT (T308), pTSC2 (T1462), p-p70S6k 
↓ iNOS, pro-IL1β, COX2 













sity (60% kcal 
from fat) 
10–50 μM (C. elegans and 
C2C12 myoblasts) 
 
25 mg/kg/day in food pel-
lets (rat studies) 
 
50 mg/kg/day in food pel-
lets (mouse studies) 
↑ survival, pharyngeal pumping per min, mobility, muscle fiber or-
ganization 
↑ cco-1, phi-37, mev-1, sdha-1, and O2 consumption by day 8 in C. 
elegans 
↑ formation GFP-LGG-1-positive punctae, mitochondrial content in 
muscle and intestine by day 5 C. elegans 
 
↑ LC3-II/LC3-I ratio in intestinal cells and ubiquitination and 
p62/SQSTM in mitochondrial fraction of intestinal cells, phospho-




↓ basal O2 consumption, ATP content  
↑ grip strength, running distance (km), p-AMPKα, LC3II, ↓ p-62, ↑ 







10 mg/kg/BW gavage 
10 μg/mL 
↑ VEGFA, CDH5 
[36] ↑ SIRT1, PGC-1a 
↑ ATP and NAD+ levels 
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UroA administration is specified for rodent and human studies; for cell studies, dose is in indicated in μM. Akt, protein 
kinase B; AMPKa, AMP-activated protein kinase alpha; BMDM, bone marrow-derived macrophages; BW, body weight;  
FMT, fecal microbiota transplantation; HF, high fat; IL1b, interleukin 1-beta; IL6, interleukin 6; IL10, interleukin 10; LPO, 
lactoperoxidase; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; MPO, myeloperoxidase; NAD+, nicotin-
amide adenine dinucleotide; NF-κB, nuclear factor-kappa B; NO, nitric oxide; ROS, reactive oxygen species; Sirt-1, sirtuin 
1; TNFa, tumor necrosis factor. 
2.3. Modulation of Autophagy by UroA 
Beyond inhibition of NFκB activation, UroA enhances autophagy under inflamma-
tory conditions to enhance cell viability. Using J774.1 murine macrophage stimulated with 
LPS, Boakye et al. demonstrated that UroA suppressed the pro-inflammatory M1 macro-
phage polarization and subsequently dampened pro-inflammatory cytokine secretion 
[34]. Furthermore, UroA inhibited M1 macrophage polarization by increasing autophagic 
flux, which is necessary for impeding nuclear translocation for the activation of 
Akt/mTOR signaling pathways [34]. To further support evidence of UroA’s mechanism 
of action as autophagy, Ryu et al. illustrated UroA’s function in promoting mitophagy in 
Caenorhabditis elegans (C. elegans) nematode and rodents. UroA administration (1) ex-
tended survival and lifespan in C. elegans, (2) improved mitochondrial function to sup-
press aging C. elegans and rodents, and (3) promoted the survival and increase muscle 
function via mitophagy in rodents [35]. Likewise, UroA increased skeletal muscle function 
by increasing ATP and NAD+ levels through Sirtuin 1 (Sirt1) and the peroxisome prolif-
erator-activated receptor gamma coactivator 1-alpha (Pgc1α) upregulation, thereby con-
necting UroA’s enhancement of mitochondrial function [36]. To summarize, current liter-
ature supports the notion that UroA acts on inflammation and aging by promoting mito-
chondrial function, specifically mechanisms dependent on mitophagy (Table 1). 
3. Impact of UroA on Immunometabolic Diseases 
3.1. Neuroinflammation and Neurodegenerative Diseases 
In the past year, the focus on UroA’s ability to mitigate neuroinflammation has in-
creased, with increasing evidence displaying UroA’s ability to cross the blood–brain bar-
rier (BBB) characterized in silico and in vivo [37–39]. In a neuroinflammatory environ-
ment, microglia polarize toward a pro-inflammatory state and release a stream of pro-
inflammatory cytokines including IL6, TNFα, and nitric oxide (NO) [40]. Upon secretion, 
these cytokines generate a pro-inflammatory environment that allows for protein dys-
function, such as seen in Alzheimer’s disease (AD), and rampant apoptosis [41]. 
As UroA exerted anti-inflammatory properties in macrophages, UroA inhibited neu-
roinflammation in aged transgenic R1.40 mouse hippocampus, human neuroblastoma 
cells, and BV2 mouse microglial cells [42]. UroA decreased total NO concentration and 
pro-inflammatory cytokines IL6 and TNFα, as well as increasing cell viability by inhibit-
ing apoptosis [42]. Therefore, UroA is shown to prevent overactivation of microglia by 
preventing neuroinflammation and decreasing apoptotic pathways to enhance neuron 
cell viability. Xu et al. also finds that UroA is able to prevent neuroinflammation in BV2 
mouse microglial cells upon stimulation by LPS. Comparably, Xu et al. find UroA reduces 
NO production, inhibits pro-inflammatory cytokines; furthermore, UroA suppressed the 
NFκB signaling pathway, MAPK signaling pathway, and the PI3K/Akt pathways [43], 
similar to UroA’s influence on immune cells outlined above. Low concentrations of UroA 
suppressed apoptosis and ROS production through regulation of the p38-MAPK [44] and 
increasing AMPKα [45], suggesting UroA as a promising metabolite in mediating the det-
rimental effects of oxidative stress consistent in neurodegenerative diseases. Furthermore, 
UroA suppresses oxidative stress and confers neuroprotection in Neuro-2A cells by acting 
as a radical scavenger and enzyme inhibitor of oxidases to suppress inflammation [46]. 
Therefore, UroA consistently exerts anti-inflammatory actions inhibiting NFκB signaling 
pathways and mediating oxidative stress in neuronal cells. 
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Given AD pathology is associated with reactive gliosis, inflammatory environments 
within the brain produce proinflammatory cytokines, increase amyloid precursor protein 
(APP) expression, and promote Amyloid β (Aβ) deposits in the brain [47]. In vivo, UroA 
reduced neuroinflammation in APP/PS1 transgenic female mice exhibiting an AD patho-
physiology [48]. Specifically, UroA has been shown to prevent learning and memory def-
icits; deter cell death; and alleviate plaque production, Aβ levels, and reactive gliosis [48]. 
One possible mechanism for UroA’s ability to reduce Aβ levels would be autophagy, de-
pending on mitochondrial function. In microglial and neuronal cells, low concentrations 
of UroA is potent in inhibiting NFkB acetylation and Aβ production through activation of 
autophagy and Sirt-1 [49]. Furthermore, another aging mouse model reported UroA acti-
vated miR-34-a to induce SIRT1/mTOR signaling [50]. Using a d-galactose aging mouse 
model, an oral administration of UroA prevented a brain-related aging disease by induc-
ing hippocampal autophagy, as well as suppressing inflammation [50]. Since UroA re-
search suggests macroautophagy or specifically mitophagy may be a targeted benefit, Ah-
san et al. sought to understand UroA’s mechanism on mitophagy versus autophagy to-
ward suppressing inflammation. In mice and neuroblastoma cells, UroA reduced cell in-
jury and modulated ER stress through upregulation of autophagy [51]. In contrast to pre-
vious studies, Ahsan et al. reported that UroA does not activate mitophagy but rather 
enhances general macro-autophagy to confer neuroprotection [51]. It is still controversial 
whether UroA exerts protection through general autophagy, mitophagy, or autophagy in 
conjunction with mitochondrial function. Nonetheless, UroA consistently protects against 
neuroinflammation, as summarized in Table 2.
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Table 2. Metabolic function of UroA. 
Category Test model 
Disease Type/ 
Treatment 
Dose (UroA) Metabolic Response Ref. 
Neuro 
R1.40 mouse hippocampal tissue 
SH-SY5Y neuroblastoma 
BV-2 mouse microglia 
LPS for AD model 10 μM 
↓ total NO 
↓ IL-6 and TNFα 
↑ cell viability 
↓ caspase 9, caspase 3/7 release  
[42] 
Neuro BV-2 mouse microglia LPS inflammation 3- 30μM 
↓ NO, TNFα, IL-6, iNOS, COX2, IL-1β 
↓ supernatant TNFα, IL-6, IL-1β  
↑ IkBα  
↓ nuclear p65, p-p65, p-IkBα 
↓ p-ERK 1/2, p-p38, p-Akt 
[43] 
Neuro SK-N-MC human neuroblastoma Neuroblastoma 1–5 μM 
↑ cell viability 
↓ intracellular ROS levels 
↓ Bax/Bcl2 ratio  
↓ CytC, cleaved caspase9, cleaved caspase3, cleaved PARP  
↓ p-p38/p38  
[44] 
Neuro MCAO SPF mice Cerebral ischemia 
1.5–2 mg/kg/BW in 
food pellets 
↑ mNSS, ↓ spatial memory deficits  
↑ BrdU+ cells, DCX+ cells in dentate gyri  
↓ TUNEL-positive cells  
↓ Bax, Caspase 3, and ↑ Bcl2  
↓ Il-6, Iba1 cells in hippocampus, Tnfα, Il-1β, GFAP+ cells in hippocampus  
↑ p-AMPKα, p-Ikbα  
↓ p-Akt/Akt, p-p65 NFκB/p65NFκB, p-ERk1/2, p-JNK, p-p38 
[45] 
Neuro Neuro-2a cells H2O2 treatment 0.5–20 μM 
↓ ROS  
↓ TBARs 
↑ catalase activity, SOD, GR activity, GPx activity  
↑ Prdx1, Prdx3 
[46] 
Neuro APP/PS1 transgenic mice Neuroinflammation 
300 mg/kg BW UroA 
orally 
↑ learning and memory deficits 
↓ cell death 
↑ hippocampal neurogenesis 
↓ Aβ plaque number 
↓ Il-1β, Il-5, Tnfα 
↑AMPKα 
↓ p-p65 NFκb, p38 MAPK, Bace1, APP 
[48] 
Neuro 
BV-2 mouse microglia, HEK293, ReNcell VM 
cells 
LPS inflammation 2.5–10 μM 
↓ nitrite, TNFα, IL-6  
↓ phospho-p65, acetyl-p65  
↑ SIRT1  
↑ autophagy  
[49] 
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↓ LDH release (p < .001) 






↑ miR-34a mediated SIRT1/mTOR signaling pathways  
[50] 
PC12 rat cells 50, 30, 10 μg/mL Inhibit apoptosis by ↑ autophagy 
Neuro 
C57Bl/6 mice 
MCAO focal cerebral is-
chemia 
2.5 or 5 mg/kg/BW in-
traperitoneal injection 
↓ LDH (U/L) in N2a and primary neuronal cells  
↑ autophagy LC3 puncta in mCherry-LC3 transfected N2a cells and primary 
neurons  
↑ LC3 II protein (N2a and primary neurons)  
↓ p62 in mice brains  
↓ ATF6, CHOP mRNA in N2a cells and brains  
↓ infarct volume (%) and Neurological Deficit Score in mice 
[51] 
Neuro-2a neuroblastoma 3–30 μM 
CVD 
Ea.hy926 
HUVEC endothelial cell 
Diabetic Vascular disease 10 μM ↓ p-Akt Ser473/Akt total  [52] 
CVD A7r5 VSMC 
Vascular smooth muscle 
dysfunction 





1 mg/kg/BW UroA in-
traperitoneal injection 
↓ INF/AAR and INF/LV, TUNEL-positive cells,  
↑ Ejection Fraction, Fractional Shortening, and ↓ CK, LDH  
↓ ROS, MDA and ↑ SOD  
↑ Cell viability  
↑ p-PI3K/total PI3K, p-Akt/total AKT, Bcl-2/Bax, and ↓ cleaved caspase 3 
[54] 
Neonatal rat cardiomyocytes 10 μM 
CVD HAECs oxLDL 0.5–5 μM 
↓ LDH concentration  
↑ NO and eNOS  
↓ ICAM-1 and MCP-1 mRNA  
↓ IL-6, ET-1 and ↑ PPARγ  
↓ TNFα  
↓ p-ERK/ERK, IL-6, ↑ PPARγ 
[55] 
CVD Wistar rats Atherosclerosis 3 mg/kg/BW orally 
↓ serum TC, TG, LDL  
↓ p-Erk and AT1, ↑ SR-B1 aortic tissue  
↓ chemotaxis by RANTES and MCP-1  
↑ HO-1, NQO-1, Nrf2 activity  
↓ foam cells  
[56] 
CVD RAW 265.7 Atherosclerosis 5–20 μM 
↓ intracellular cholesterol  
↑ extracellular cholesterol  
↓ p-ERK, SREBP1  
↑ p-AMPKα  
↓ miR-33a  
↑ ABCA1 and ABCG1  
[57] 
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↓ lipogenesis, Fas, aP2, PPARγ, CEBPα, ATGL, SCD-1 
↑ p-AMPKα  







10 and 50 
μM 
↓ Triglycerides  




3T3-L1 preadipocytes Lipogenesis 25 μM 
↓ intracellular triglyceride  
↓ PREF-1  
↓ Glut4, Adiponectin, Leptin  







30 mg/kg/day gavage 
↓ BW gain, fat mass and plasma glucose  
↑ glucose uptake  
↑ EE  
↑ thermogenesis  








toneal injection  
↓ blood total cholesterol, LDL  
↑ plasma adiponectin  
↓ liver triglycerides,  
↓ Huh7 lipogenesis  
↓ epidydimal adipose hypertrophy 
↑ mitochondrial biogenesis  
↓ M1 macrophage markers Cd11c & Tnfα IL-6 & Mcp1 & IL1β  







Wistar rats Obesity 
2.5 mg/kg/BW 
intraperitoneal injection 
↓ body weight  
↓ TBARS, ↑ SOD  
↓ hepatic lipids, hepatic TG, hepatic chol, fecal lipid load  





DBA2/J mice  
HF/HS diet induced IR 
and Obesity 
0.1% supplemented in 
diet 
↓ fasting glucose concentration  
↓ serum FFA, ↑ serum adiponectin,  
↑ Pink1, Prkn, Mfn2 in liver; Mfn2 in skeletal muscle 
[65] 
UroA administration is specified for rodent and human studies; for cell studies, dose is in indicated in μM. AD, Alzheimer’s disease; APP, amyloid precursor 
protein; eNOS, endothelial nitric oxide synthase; ET, ellagitannins; FABP4, fatty acid-binding protein 4; FFA, free fatty acids; GLUT4, glucose transporter type 4; 
GR, glutathione reductase; GPx, glutathione peroxidase; HS, high sugar; LDL, low-density lipoprotein; MAPK, mitogen-activated protein kinase; MDA, malondial-
dehyde; oxLDL, oxidized low-density lipoprotein; SOD, superoxide dismutase; TBARs, thiobarbituric acid-reactive products; TC, total cholesterol; TG, triglycerides. 
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3.2. Cardiovascular Disease 
In response to toll-like receptor 4 (TLR4) stimulation, Akt reaches the plasma mem-
brane of the cell and allows for secretion of various cytokines [66]. Interestingly, depend-
ing on the activation signal, Akt can result in either pro-inflammatory or anti-inflamma-
tory responses [66], modulating M1/M2 polarization [67]. In endothelial cells, PI3K/Akt is 
important for vascularization and is responsible for anabolic processes [52]. However, 
over-activation of Akt plays a role in the pathogenesis of diabetic vascular activation [52]. 
UroA subdued Akt signaling pathways in human endothelial cells for management of 
type 2 diabetes mellitus, possibly due to its unique chemical structure as other urolithins 
failed to exhibit similar actions [52]. UroA regulated Akt/β-catenin signaling pathways in 
vascular smooth muscle cells by suppressing the phosphorylation of Akt at the residue 
Threonine 308, as well as modulating β-catenin pathways, to reduce ROS and inflamma-
tion [53]. In vivo, the cardioprotective effects of UroA were investigated in a mouse model 
of myocardial reperfusion injury, defined as extensive tissue damage occurring after 
blood supply is restored post-ischemic injury or period of hypoxia [54]. UroA reduced 
ROS production by regulating the PI3K/Akt pathway and enhancing antioxidant activities 
in mice and cardiomyocytes [54]. In contrast to the previous two studies, UroA attenuated 
myocardial injury by activating the PI3K/Akt signaling to reduce apoptosis [54]. In sum-
mary, regarding vasculature and endothelial cells, UroA regulates the PI3K/Akt pathway 
and downstream targets to limit inflammation after cardiovascular injury, however more 
research is needed to confirm the clinical benefits of UroA against ischemia or hypoxia. 
Inflammation and endothelial dysfunction exacerbate atherosclerosis [68]. Moreover, 
oxidized low-density lipoprotein (oxLDL) is a hallmark of atherosclerotic pathophysiol-
ogy. With an increase of oxLDL, endothelial dysfunction occurs due to increases in in-
flammation and impairment of NO which is vital for endothelial function [69]. Han et al. 
investigated UroA’s effect on impairing oxLDL-induced endothelial dysfunction and in-
flammation in human artery endothelial cells treated with oxLDL. Low concentrations of 
UroA were shown to increase NO production due to improvement of endothelial nitric 
oxide synthase (eNOS), decrease monocyte adhesion factors such as ICAM-1, and de-
crease ERK-mediated inflammation along with IL6 and TNFα [55]. Therefore, UroA con-
fers protection against endothelial dysfunction caused by oxLDL through reduction of 
inflammation and restoration of NO production. Atherosclerosis is multifaceted and ox-
LDL is but one factor for inducing its inflammatory pathophysiology. As atherosclerosis 
progresses, cardiac ischemia may occur due to scavenger receptor-class B type 1 (SR-B1) 
inhibition as SR-B1 mediates cholesterol transport of high-density lipoprotein (HDL) to 
the liver and reduces atherosclerotic plaque formation [56]. Cui et al. further examines 
whether UroA is able to attenuate atherosclerotic lesions in rats fed a high-cholesterol diet 
and subjected to a balloon injury of the aorta. UroA reversed inflammatory lipid levels, 
decreased levels of angiotensin II, and decreased foam cell development through activa-
tion of the Nrf2 pathway and inhibition of p-ERK [56]. Additionally, in macrophage foam 
cells, UroA suppressed mIR-33-a by altering ERk/SREBP1/AMPKα signaling pathways to 
regulate cholesterol efflux to reduce intracellular cholesterol load [57]. Lastly, UroA im-
proved hemodynamics and decreased inflammation of CX3CL1 in a rat model of diabetic 
cardiomyopathy [58]. In all, UroA confers protection against atherosclerosis by restoring 
NO production, mediating cholesterol transport, and regulating ERK signaling pathways 
(Table 2). 
3.3. Obesity, Type 2 Diabetes, and Metabolic Syndrome 
A precursor to cardiovascular disease (CVD) is obesity and associated metabolic syn-
drome. Obesity is detrimental to health and is associated with the induction of metabolic 
syndrome. Metabolic syndrome is classified as high waist circumference, elevated triglyc-
erides, reduction of high-density lipoprotein cholesterol, high blood pressure, and high 
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fasting blood glucose [70]. In individuals with three classical metabolic syndrome risk fac-
tors fed 30 g of raw nuts for 12 weeks, UroA glucuronide was found to be at the highest 
concentration in plasma [71]. Moreover, UroA glucuronide in plasma was inversely cor-
related with abdominal adiposity defined by waist circumference [71]. Therefore, in a hu-
man population, the UroA conjugate, UroA glucuronide, reversed metabolic syndrome as 
shown in abdominal adiposity. 
Mechanistically, Kang et al. reported UroA (in addition to UroC and UroD) attenu-
ated triglyceride accumulation in both human adipocytes and hepatocytes by decreasing 
lipogenic gene expression [59]. UroA increased fatty acid oxidation through AMPK-de-
pendent mechanisms to decrease triglyceride accumulation [59]. In 3T3-L1 murine pre-
adipocytes, UroA decreased triglyceride content and abolished the expression of PPARγ, 
Glut4, and FABP4 in pre-adipocytes [60] and dampened lipogenesis without impairing 
adipogenesis [61]. Recent studies suggest UroA protects against high-fat-diet-induced 
obesity and related insulin resistance. With gavaging UroA, mice were protected from 
high fat diet-induced obesity and insulin resistance through augmentation of thermogen-
esis stimulated by thyroid hormone signaling to induce browning [62]. Toney et al. also 
demonstrated UroA’s beneficial effects using an in vivo model of C57BL/6 mice fed a high-
fat diet and injected intraperitoneally with UroA daily for 90 days [63]. UroA improved 
insulin sensitivity, decreased hepatic triglyceride accumulation and inflammation, and 
decreased adipose tissue macrophages and hypertrophy by inhibiting M1 macrophage 
polarization while promoting M2 macrophage polarization and mitochondrial function 
[63]. In supporting this study, daily intraperitoneal injection of UroA protected rats 
against high fat diet-induced obesity by attenuating oxidative stress, decreasing lipogen-
esis and providing antioxidative protection [64]. On the contrary, in DBA2/J mice fed a 
high-fat/high-sugar diet, UroA supplementation in the diet (0.1%) decreased fasting blood 
glucose, but failed to improve insulin sensitivity; however, compared to its EA precursor, 
UroA supplemented diet increased adiponectin and improved mitochondrial function in 
the liver and skeletal muscle, consistent with UroA beneficial mechanisms in multiple dis-
ease states [65]. This difference between studies could be due to supplementation of UroA 
(diet versus injection/gavage), diet intensity (high fat versus high fat/high sugar)/duration 
or experimental animal model. More studies are summarized in Table 2. From the sum-
mary of these studies, UroA attenuated obesity and metabolic syndrome seen both in vivo 
and in vitro. For future study direction, more research is warranted to define the exact 
mechanisms involving the gut microbiome to elicit these health benefits. 
3.4. Nephrotoxicity 
For chemotherapy patients using cisplatin, nephrotoxicity can occur as a side effect 
to this drug or in combination with other chemotherapy drugs. Several studies have 
demonstrated the effectiveness of intraperitoneal injection or orally administered UroA in 
attenuating nephrotoxicity in mice. UroA treatment prevents cisplatin-induced ne-
phrotoxicity in Sprague-Dawley rats by decreasing pro-inflammatory cytokines while in-
creasing IL-10; moreover, UroA decreased NFκB activation and inhibited proapoptotic 
pathways [72]. In another study, UroA provided protection against cisplatin-induced ne-
phrotoxicity due to its anti-oxidant and anti-inflammatory properties [73]. Only using 100 
mg/kg per day intraperitoneal injection, researchers found that UroA modulated oxida-
tive stress and inflammation caused by cisplatin by reducing pro-inflammatory cytokines, 
infiltrating leukocytes, and reactive oxygen species production [73]. Within the kidney, 
UroA induced autophagy, to protect against ischemia-reperfusion injury (IRI) and kidney 
dysfunction, by decreasing TNFα and IL-1β secretion [74] (Table 3). 
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Table 3. UroA in kidney disease. 
Category Test model 
Disease Type/ 
Treatment 




Cisplatin 50 mg/kg BW orally 
↓ plasma creatinine levels  
↑ protection against epithelial necrosis  
↓ TIM-1, NFκB expression, Iba1, TNFα, IL-6, IFNγ, IL-1α, IL-1β, IL-
13, IL-17A, IL-2 
↑ IL-10 and NOS-3 
↓ tubular cell apoptosis (number of TUNEL positive cells) 
[72] 
Kidney C57Bl/6 mice Cisplatin 
100 mg/kg BW intra-
peritoneal injection 
↓ NGAL, BUN, Creatinine, Urinary KIM-1 
↓ tubular damage score  
↓ TNFα, IL-23, IL-18, MIP2  
↓ CD11b positive cells in kidney 
↓ HNE Protein Adducts Protein Nitration, Caspase 3 activity, DNA 
fragmentation  
↑ GSH, GSH/GSSG ratio, ↑GSSG  
↓ NOX2  
↑ Glutathione Peroxidase Activity and SOD activity  
[73] 
Kidney C57BL/6 mice 
Ischemia reper-
fusion injury 
50 mg/kg BW 
(not specified) 
↓ BUN, NGAL, Creatinine, KIM-1  
[74] 
↓ TNFα, IL-1β, MIP-1α, MIP2 
UroA administration is specified for rodent and human studies; for cell studies, dose is in indicated in μM. BUN, blood 
urea nitrogen; GSH, glutathione; GSSG, glutathione disulfide; NGAL, neutrophil gelatinase-associated lipocalin;  
4. Development of UroA as a Therapeutic 
As summarized in Tables 1–3, UroA is a promising biomarker for gut health and gut 
composition, based on its health-benefitting effects driven by the gut microbiota and host 
metabolism [75]. Moreover, UroA can potentially be used as a cardiometabolic biomarker 
in humans [76]. Given that UroA’s beneficial effects on gut health has been established in 
the past decade, using UroA as a biomarker may correlate health status among gut, met-
abolic, and neurological samples, for future prevention purposes. However, bioavailabil-
ity of either ellagic acid or its gut metabolite UroA may pose a problem in its potency, as 
polyphenol bioavailability is limited, and emerging research involving metabotypes sug-
gest the host’s microbiota plays a role in producing UroA. 
Recently, advances have been made to increase the availability of UroA in similar 
synthetic forms. Singh et al. developed a synthetic analogue to UroA, named UAS03, 
which has been shown to resist stomach acid degradation, increase gut health through 
enhanced barrier function, and reduce inflammation throughout the host [77]. Essentially, 
UAS03 is a generated non-hydrolysable cyclic ether derivative of the naturally occurring 
gut metabolite UroA; however, it remains stable [77]. Therefore, focusing efforts on stably 
producing the effects of UroA through pharmaceutical advances may provide future ther-
apeutics for various diseases. 
Moreover, as UroA continues to be tested in a human population, its health benefits 
are being better understood. Recently, Andreux et al. found that UroA packaged in en-
capsulated soft gels for oral administration in an elderly population is safe and mimics an 
exercise response in muscle, due to its mitochondrial activities [78]. In this healthy popu-
lation, they did find that conjugated UroA metabolites were found at higher concentra-
tions, thereby suggesting under a healthy participant UroA undergoes phase-two conju-
gation [78]. Lastly, they found that UroA administration increased fatty acid oxidation 
and mitochondrial function in human skeletal muscle despite a sedentary trial [78]. In-
creasing evidence suggesting UroA as a potential exercise mimetic is warranted and may 
provide a clue for combating obesity and related disease. 
Despite one method of orally ingesting UroA in an encapsulated form, other research 
should focus on developing the targeted delivery of the parent compound UroA, instead 
of its conjugated forms, to various target tissues and organs using nanotechnology. One 
suggestion is to research modes of delivery using nanoparticles encapsulating UroA. As 
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of now, one study has focused on developing a biodegradable nanoparticle to package 
UroA to increase bioavailability; this has been tested only in mice, but it has shown prom-
ising results in protecting against acute kidney injury, improving survival rate, and miti-
gating oxidative stress [79]. In the case of pomegranate bioactive compounds, researchers 
found that pomegranate nanoprototypes are able to decrease proliferation of breast cancer 
cells by increasing bioavailability [80]. However, these findings for this pomegranate na-
noprototype and UroA biodegradable nanoparticle need to be further tested in humans, 
for translational implications. 
Lastly, another method of increasing UroA efficacy is through fecal microbiota trans-
plants (FMTs), which have gained traction in the clinical field. FMT is mainly used for 
treating Clostridium difficile infection which is antibiotic resistant [81]. FMT uses a healthy 
donor’s stool to reach the recipient’s intestine, where the healthy microbial community is 
able to colonize and enact changes in the microbiome [81]. In terms of UroA delivery, 
metabotype 0 individuals who do not possess the microbes to convert ellagic acid to UroA 
may be eligible for FMT from a metabotype A donor. In doing so, this can potentially 
allow metabotype A microbes to colonize the recipient’s microbiome and allow for UroA 
conversion and functionality. However, this warrants further research, and donor screen-
ing practices will need specific criteria in order to prevent transfer of infection or other 
adverse reactions. 
5. Conclusions 
Chronic inflammation induces various metabolic pathologies in the brain, heart, ad-
ipose, and kidney. In this review, we focused on the current developments in UroA re-
search concerning immune modifications, neuroinflammation, metabolic and cardiovas-
cular diseases, and nephrotoxicity. Moreover, we proposed UroA’s mechanisms of action 
in attenuating these diseases by targeting mitochondrial function, induction of autophagy, 
mitigation of MAPK/NFkB/Akt signaling, and reduction of ROS and pro-inflammatory 
cytokines in multiple tissues. Currently, UroA is being investigated as a potential phar-
macological disease-modifying oral supplement due to its various biological effects in 
promoting mitophagy and limiting inflammation. Moreover, research focused on discern-
ing the different metabotypes, its relation to urolithin production, and gut microbes asso-
ciated with these metabotypes will yield answers toward the conversion of ellagic acid 
into various bioavailable urolithins for individuals with unique microbiomes and health 
conditions. Therefore, future research focused on elucidating the conversion of EA into 
urolithins and the safe efficacy of using UroA as a drug can yield promising therapeutics. 
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Akt protein kinase B 
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Ab amyloid beta 
APP amyloid precursor protein 
BBB blood–brain barrier 
C. elegans Caenorhabditis elegans 
CRP C-reactive protein 
EA ellagic acid 
Biomedicines 2021, 9, 192 14 of 18 
 
ET ellagitannins 
eNOS endothelial nitric oxide synthase 
FABP4 fatty acid-binding protein 4 
FMT fecal microbiota transplantation 
GLUT4 glucose transporter type 4 
HDL high-density lipoprotein 
IL1b interleukin 1-beta 
IL6 interleukin 6 
IL10 interleukin 10 
iNOS inducible nitric oxide synthase 
LPS lipopolysaccharide 
MAPK mitogen-activated protein kinase 
MPO myeloperoxidase 
NF-κB nuclear factor-kappa B 
NO nitric oxide 
oxLDL oxidized low-density lipoprotein 
PMA phorbol myristate acetate 
PPARg peroxisome proliferator activated receptor gamma 
ROS reactive oxygen species 
Sirt-1 sirtuin 1 
TLR4 toll-like receptor 4 
TNFa tumor necrosis factor 
UM-A urolithin metabotype A 
UM-B urolithin metabotype B 
UM-0 metabotype 0 
Uro urolithin 
UroA urolithin A 
UroB urolithin B 
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